Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PITAC for Malignant Pleural Effusion (OPC5)
NCT06421610Phase 1Recruiting
- Sponsor
- University Hospital Odense
- Start
- Sep 2023
- Primary completion
- Dec 2024
- Modality
- DNA Intercalators/Alkylators, Targeted Liposomes, Stealth (PEGylated) Liposomes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Cisplatin micelle injection (HA132), pegylated liposomal doxorubicin and oxaliplatin in malignant pleural effusion (MPE), sponsored by University Hospital Odense. Primary endpoints: Medical adverse events according to CTCAE at 30 days and Surgical complications according to Clavien-Dindo at 30 days. Started Sep 2023; status: recruiting.
02
Drugs
Cisplatin micelle injection (HA132)pegylated liposomal doxorubicinoxaliplatin
03
Conditions
malignant pleural effusion (MPE)
Beyond the preview
Go deeper on NCT06421610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06421610.